Concepedia

Author

Dawn Baker

AstraZeneca (United Kingdom)

Also Known As

Baker, D, D.D. Baker, Dawn Baker

16

Publications

1.1K

Citations

9

H-Index

33

Concepts

All Affiliations

AstraZeneca (United Kingdom)AstraZeneca (United States)
DB

About

Dawn Baker is an author at AstraZeneca (United Kingdom) specializing in tumor biology, cell biology, and medicine.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

5

5

598

2

Cell Biology

5

5

598

3

Natural Sciences

1

1

11

4

Immunology

1

1

51

5

Molecular Biology

1

1

28

Dawn Baker

×

9

Publications

1.1K

Citations

9

H-Index

YearCitations

AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family

Paul R. Gavine, Lorraine Mooney, Elaine Kilgour,

Cancer Research

2012

491

Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 Are Localized Primarily to the Vasculature in Human Primary Solid Cancers

Neil R. Smith, Dawn Baker, Neil H. James,

Clinical Cancer Research

2010

236

Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy

Neil R. Smith, Dawn Baker, Matthew R. Farren,

Clinical Cancer Research

2013

134

The Effect of VEGF-Targeted Therapy on Biomarker Expression in Sequential Tissue from Patients with Metastatic Clear Cell Renal Cancer

Kevin Sharpe, Grant D. Stewart, Alan Mackay,

Clinical Cancer Research

2013

68

MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis <i>In Vivo</i>

David W. Jenkins, Sarah J. Ross, Margaret H. Veldman-Jones,

Molecular Cancer Therapeutics

2012

51

Characterization of FGFR1 Locus in sqNSCLC Reveals a Broad and Heterogeneous Amplicon

Claire Rooney, Catherine Geh, Victoria Williams,

PLoS ONE

2016

28

Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547

Oona Delpuech, Claire Rooney, Lorraine Mooney,

Molecular Cancer Therapeutics

2016

26

Exploratory biomarker analysis of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors.

Elaine Kilgour, David Ferry, Matilde Saggese,

Journal of Clinical Oncology

2014

17

Abstract 3568: Characterization of AZD4547: An orally bioavailable, potent and selective inhibitor of FGFR tyrosine kinases 1, 2 and 3

Paul R. Gavine, Lorraine Mooney, Elaine Kilgour,

Cancer Research

2011

11

Page 1